Frontline Alectinib Recommended for EU Approval for ALK+ NSCLC

October 13, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of alectinib for the first-line treatment of adults with ALK-positive, advanced non–small cell lung cancer (NSCLC). Based on phase III results from the ALEX trial showing that the second-generation ALK-inhibitor significantly reduced the risk of progression or death compared with crizotinib, the agency has also simultaneously … (leggi tutto)